SELLAS Life Sciences Group, Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

SLS$8.42+6.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

	March 31, 2026	December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$107,097	$71,793
Restricted cash and cash equivalents	100	100
Prepaid expenses and other current assets	3,972	3,318
Total current assets	111,169	75,211
Operating lease right-of-use assets	839	963
Goodwill	1,914	1,914
Deposits and other assets	255	257
Total assets	$114,177	$78,345
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$3,633	$2,948
Accrued expenses and other current liabilities	2,261	3,525
Operating lease liabilities	562	544
Total current liabilities	6,456	7,017
Operating lease liabilities, non-current	309	457
Total liabilities	6,765	7,474
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 181,332,574 and 153,103,459 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	18	15
Additional paid-in capital	390,789	345,844
Accumulated deficit	(283,395)	(274,988)
Total stockholders’ equity	107,412	70,871
Total liabilities and stockholders’ equity	$114,177	$78,345

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.